Press release
March 11, 2015
Occupational Hazards in Interventional Cardiology to be Highlighted by Corindus Vascular Robotics at American College of Cardiology’s 64th Annual Scientific Session & Expo, Mar. 14 - 16

Waltham, MA – March 11, 2015Corindus Vascular Robotics, Inc. [OTCQB: CVRS], a leading developer of precision vascular robotics, will showcase its CorPath® System at the upcoming American College of Cardiology’s (ACC) 64th Annual Scientific Session & Expo, March 14 – 16 in San Diego, CA.

The CorPath System is the first FDA-cleared medical device to provide robotic-assistance in PCI procedures. It enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure. The CorPath System's proprietary technology allows cardiologists to advance stents and guidewires millimeter-by-millimeter using digital controls.

“The Interventional Cardiology community has only recently focused on the occupational hazards in the cath lab and on efforts to minimize health risks to physicians,” said Michael Ragosta, M.D., Medical Director for Interventional Cardiology, University of Virginia Health System. “Our facility is utilizing technologies such as the CorPath System to greatly reduce our radiation exposure and reduce our risk of orthopedic injury and disability.”

Occupational Health Hazards of Working in the Interventional Laboratory,” a study recently published in the Journal of the American College of Cardiology (JACC), found that musculoskeletal pain was more common among healthcare workers participating in interventional procedures. in his editorial comment included in the same issue of JACC, James A. Goldstein, M.D. reiterated that operator safety must be prioritized and innovations, such as robotics, can create healthier workplaces for physicians.

Occupational safety and additional benefits of robotic PCI will also be highlighted in a presentation at ACC.15 provided by Giora Weisz, M.D., Chairman of Cardiology, Shaare Zedek Medical Center, as part of Scientific Session 2634 – Optimizing PCI Care Processes. The CME/CNE accredited session will take place on Monday, March 16, in room 6F.

“There are a growing number of voices pushing for improved standards of safety in interventional cardiology, reinforcing that the issue of cath lab occupational hazards is becoming a priority within hospitals,” said David Handler, President and CEO, Corindus Vascular Robotics. “It is important that our industry aligns in support of those providing care. We believe that hospitals should empower and protect their interventional cardiologists with the safety of new technologies.”

To learn more about the CorPath System, visit booth #1937 at ACC.15. For additional information, visit

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window